Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial-Reference-Cited by-同舟云学术

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

Published:2013-06-10 Issue:11 Volume:98 Page:1726-1731
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Mounier N.,El Gnaoui T.,Tilly H.,Canioni D.,Sebban C.,Casasnovas R.-O.,Delarue R.,Sonet A.,Beaussart P.,Petrella T.,Castaigne S.,Bologna S.,Salles G.,Rahmouni A.,Gaulard P.,Haioun C.

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

2. The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain;Cancers;2024-07-30

3. Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study;Cancer Medicine;2024-07

4. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group;Clinical Cancer Research;2024-06-20

5. Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma;European Journal of Haematology;2024-06-10